ATLG血清水平对儿童单倍体HSCT中CD3/CD19去除移植物及免疫重建的影响
该回顾性研究在儿童单倍体CD3/CD19去除移植中,将ATLG起始日移至-12天并测定3种剂量(15、30、60 mg/kg)的T细胞特异性血清浓度,第0天均值分别为1.14、2.99、12.10 μg/mL。高剂量与更高峰值及更低排斥相关,低剂量与更快的T及NK细胞恢复相关,GVHD率保持低位且与剂量无关。
要点
- 第0天T细胞特异性ATLG血清浓度均值:15 mg/kg组1.14、30 mg/kg组2.99、60 mg/kg组12.10 μg/mL。
- 较高ATLG剂量与第-8和-7天更高峰值水平及降低的移植物排斥相关。
- 较低ATLG剂量与移植后T细胞和自然杀伤细胞显著更快的恢复相关。
核心结论
- 该回顾性研究显示,在体外CD3/CD19去除的单倍体HSCT中,ATLG的剂量和给药时间与植入及免疫恢复相关。
研究设计与样本
- 回顾性研究,在儿童单倍体CD3/CD19去除HSCT患者中采用3种已建立的ATLG给药方案(15、30或60 mg/kg),并将ATLG起始应用移至-12天。
主要发现
- 第0天对应的T细胞特异性ATLG血清浓度均值分别为1.14、2.99或12.10 μg/mL(15、30、60 mg/kg组)。
- 较高ATLG剂量与第-8和-7天更高峰值水平及降低的移植物排斥相关,而较低ATLG剂量与移植后T细胞和自然杀伤细胞显著更快的恢复相关。
- 移植物抗宿主病发生率保持低位,且不依赖于ATLG剂量。
- 体外实验显示,ATLG浓度2.0 μg/mL及以下仅轻微降低自然杀伤细胞活性,因此此类效应细胞在移植物中的功能可能得以保留。
- 药代动力学分析与线性一级动力学相符,显示半衰期值相似且不依赖于ATLG剂量,因此可在HSCT前计算达到所需ATLG血清水平的天数。
局限性
- 该研究为回顾性研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-T lymphocyte globulin (ATLG) significantly reduces the risk of engraftment failure in allogeneic hematopoietic stem cell transplant (HSCT) but hampers posttransplant immune reconstitution. We hypothesized that in patients receiving haploidentical CD3/CD19-depleted grafts, these double-edged effects could be better balanced by attaining high ATLG serum concentrations before transplant but as low as possible on the day of transplant. Therefore, we moved the start of ATLG application to day -12 and determined serum concentrations of T-cell-specific ATLG in pediatric patients treated with 3 established dosing regimens (15, 30, or 60 mg/kg). Corresponding mean T-cell-specific ATLG serum concentrations at day 0 were 1.14, 2.99, or 12.10 μg/mL, respectively. Higher ATLG doses correlated with higher peak levels at days -8 and -7 and reduced graft rejection, whereas lower ATLG doses correlated with significantly faster posttransplant recovery of T and natural killer cells. The rate of graft-versus-host disease remained low, independent of ATLG doses. Moreover, in vitro assays showed that ATLG concentrations of 2.0 μg/mL and lower only slightly reduced the activity of natural killer cells, and therefore, the function of such effector cells might be preserved in the grafts. Pharmacokinetic analysis, compatible with linear first-order kinetics, revealed similar half-life values, independent of ATLG doses. Hence, the day on which a desired ATLG serum level is reached can be calculated before HSCT. Our retrospective study demonstrates the relevance of dosing and time of administration of ATLG on engraftment and immune recovery in ex vivo CD3/CD19-depleted haploidentical HSCT.
引用
- Maier CP, Klose C, Seitz CM, et al. Influence of ATLG serum levels on CD3/CD19-depleted hematopoietic grafts and on immune recovery in pediatric haplo-HSCT. Blood Adv. 2024. PMID: 38290133. doi:10.1182/bloodadvances.2023011016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。